Aprogen
Unparalleled biopharmaceutical innovation
Seongnam, South Korea · Founded 2000 · $26.7M raised
- Headquarters
- Seongnam
- Employees
- 201–500
- Founded
- 2000
- Business Model
- B2B
- Website
- aprogen.com
- Total Funding
- $26.7M
- Last Round
- $10.0M Private EquityMay 2026
- Rounds
- 3
About
Aprogen, founded in 2000 and headquartered in Seongnam, South Korea, is a biopharmaceutical company focused on biosimilar development and manufacturing. The company developed South Korea's first approved antibody biosimilar in 2006 and has since expanded its pipeline to include biosimilars for infliximab, trastuzumab, adalimumab, rituximab, and cetuximab, as well as novel bispecific antibody therapeutics. Aprogen is listed on the KOSPI exchange.
Summary
Aprogen is a Biotech company based in Seongnam, South Korea, founded in 2000. It has raised $26.7M in total across 3 rounds, most recently a $10.0M Private Equity round in May 2026.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2026
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...